Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels

Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels is a phase 2, randomised interventional study registered as NCT07282912 by Yale University, with a registry enrolment figure of 54 participants, started 2026-06-02 and due to reach its primary completion in 2028-06. Interventions recorded: Sequential cytoreductive intervention, Signatera Genome ultra-sensitive ctDNA blood test. Conditions listed: Foregut Adenocarcinoma, Esophageal Adenocarcinoma, Gastroesophageal Adenocarcinoma, Gastric Adenocarcinoma, Pancreas Adenocarcinoma, Duodenal Adenocarcinoma, Ampullary Adenocarcinoma, Gallbladder Adenocarcinoma, Intra - and Extrahepatic Cholangiocarcinoma. Sites: United States. No results are recorded here; the registry entry is the source.